LL-37 is studied in tissue regeneration and repair research, including cell and animal models. LL-37 has an amphipathic structure that allows it to insert into bacterial cell membranes and disrupt their integrity — a mechanism fundamentally different from classical antibiotics.
Studied in wound-healing and antimicrobial research — clinically so far only in topical form for venous leg ulcers and diabetic foot ulcers. No published human data exist for injectable use.
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Studies on regenerative peptides are mostly derived from cell culture and animal models; comprehensive clinical data is typically still limited.
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
We reply personally – via email or Telegram.